54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Langley R, Fiorentino D, Bagel J, Lafferty K, Skobelev E, Langholff W, Lebwohl M, Ho V, Strober B. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab61. DOI: 10.1016/j.jaad.2024.07.252.Peer-Reviewed Original Research54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Augustin M, Tada Y, Lafferty K, Skobelev E, Langholff W, Fakharzadeh S, Gniadecki R. 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab152. DOI: 10.1016/j.jaad.2024.07.605.Peer-Reviewed Original ResearchPsoriasis Longitudinal Assessment and RegistryInterleukin-17 inhibitorsReal-world patientsInterleukin-17